Table 2.
Summary of vitamin D replacement guidelines in the general population, identified in the MENA region.
| Author year/journal | Country | Guidelines developing groupa | Desirable 25(OH) D level | Recommendations |
|---|---|---|---|---|
| A vitamin D targeted guidelines | ||||
|
Raef et al., 2011 Ann Saudi Med |
KSA | Osteoporosis Working Group of King Faisal Specialist Hospital and Research Centre | NA |
|
|
Al-Daghri et al., 2017 Arch Osteoporos |
KSA | Prince Mutaib Chair for Biomarkers of Osteoporosis: 12 local and 2 expert advisers from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) |
|
|
|
Haq et al., 2018 J Steroid Biochem Mol Biol |
UAE | Not defined explicitly, but authors included experts in endocrinology and metabolism, biochemistry and public health | –30 ng/ml as per the Endocrine Society |
|
| B osteoporosis guidelines | ||||
| Lebanese Society for Osteoporosis and Metabolic Bone disorders (OSTEOS), 2012 | Lebanon |
Guidelines developed by: OSTEOS Guidelines endorsed by: Lebanese Society of Endocrinology; Lebanese Society of Obstetrics and Gynecology; Lebanese Association of Orthopedic Surgeons; Lebanese Society of Radiology; Lebanese Society of Rheumatology; Lebanese Society of Family Medicine; Lebanese Society of Internal Medicine; Lebanese Society of General Practitioners |
30–60 ng/ml |
|
|
Maalouf et al., 2007 J Musculo-skelet Neuronal Interact |
MENA | Not defined explicitly, but authors included experts in osteoporosis, endocrinology and metabolism | No clear statement |
|
Abbreviations: 25(OH) D: 25‑hydroxyvitamin D; ESCEO: European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis; KSA: Kingdom of Saudi Arabia; MENA: Middle East and North Africa; NA: not available; OSTEOS: Lebanese Society for Osteoporosis and Metabolic Bone disorders; UAE: United Arab Emirates.
None of the documents describe the methodology used in the guideline development process.